Gil Blum, an analyst from Needham, reiterated the Buy rating on Crispr Therapeutics AG. The associated price target remains the same with $81.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Gil Blum has given his Buy rating due to a combination of factors that highlight Crispr Therapeutics AG’s strategic positioning and potential for growth. The company’s pipeline, particularly its in vivo gene editing programs, is seen as undervalued by the market despite its promising potential to provide one-time treatment solutions for severe cardiovascular diseases. This potential is further validated by the recent acquisition of Verve by Lilly, which underscores the significance of Crispr’s approach in the broader genetic editing landscape.
Moreover, Crispr Therapeutics AG is uniquely positioned to capitalize on these opportunities due to its leading position in the industry and strong financial standing. These elements contribute to the confidence in Crispr’s ability to succeed in larger cardiovascular markets, fulfilling the broader promise of genetic editing. Consequently, Gil Blum maintains a Buy rating with a target price of $81, reflecting the anticipated value realization from these strategic initiatives.
In another report released on June 27, Citizens JMP also reiterated a Buy rating on the stock with a $86.00 price target.